Conditions for large-scale production of genetically engineered E.coli bearing humanized anti- HBsAg Fab

Abstract

Abstract: Objective To define the conditions for large-scale production of genetically engineered E.coli bearing humanized anti-HBsAg Fab. Method Characteristic growth and expression of the engineered E.coli were observed during fermentation in the shaking flask to define the optimal culture conditions to achieve the highest production levels. On the basis of the observation results, the E.coli was cultured in a fermentor using the fed-batch method to determine the optimal production techniques. Results Observation of the bacterium in the shaking flask showed initiation of the induction procedure in the mid-log growth phase at 25 ℃ with 0.2% arabinose resulted in the highest production of anti-HBsAg Fab. The D₆₀₀ value of the culture reached 55.2, equivalent to 110 g/L wet weight of the bacterium, using the DO-stat fed-batch method. The resultant Fab showed well-preserved biological activity. Conclusion Reliable techniques for rapid and massive production of the Fab have been developed.

CLC Number:

R392.11

ZHENG Da-yong¹, LUO Rong-cheng¹, CAI Hong-bin². Conditions for large-scale production of genetically engineered E.coli bearing humanized anti- HBsAg Fab[J]. Journal of Southern Medical University, 2004, 24(05): 517-520.

References

[1] Lee SY. High cell-density culture ofEscherichia coli [J]. Trends Biotechnol, 1996, 14(3): 98-105.
[2] Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli[J]. Microbiol Rev, 1996, 60(3): 512-38.
[3] 李仲宏,麦国丰,罗荣城,等.瘤内注射核素标记混合抗体治疗肝癌的实验研究[J].第一军医大学学报,2000,20(4):327-8.Li ZH, Mai GF, Luo RC, et al. Experimental studies of treatment of the liver cancer by intratumoral injection of 131I-labeled multiple monoclonal antibodies [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2000, 20(4): 327-8.
[4] 罗荣城,尤长宣,韩焕兴,等.人源乙型肝炎病毒表面抗原抗体Fab片段与IFN-α融合蛋白表达载体的筛选[J].第一军医大学学报,2000,20(2):100-3.Luo RC, You CX, Han HX, et al. Selection of the expression vector for the fusion protein of human anti-HBs antibody Fab fragment and interferon-α [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2000, 20(2): 100-3.
[5] Riesenberg D, Menzel K, Schulz V, et al. High-cell density fermentation of recombinant Escherichia coli. Expressing human interferon alpha[J]. Appl Microbio Biotechnol, 34(1): 77-82.
[6] Pluckthun A, Krebber A. Producing antibodies in Escherichia coli:from PCR to fermentation [A]. In: McCaffergy J, Hoogenboon H,Chiswell D, eds. Antibody Engineering: A Practical Approach [M].Oxford: Oxford University Press, 2001. 203-52.
[7] Luli GW, Strohl WR. Comparison of growth, acetate, production and acetate inhibition of Escherichia coli. Strains in batch and fedbatch fermentation[J]. Appl Environ Microbiol, 1990, 56(4): 1004-11.
[8] Guzman LM, Belin D, Carso MJ, et al. Tight regulation, modulation,and high-level expression by vectors containing the arabinose pBAD promoter[J]. J Bacteriol, 177(54): 4121-30.
[9] Horn V, Strittmatter W. High volumetric yields of functional dimeric miniantibodies in Escherichia coli. Using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions[J]. Appl Microbiol Biotechnol, 46(3): 524-32.
[10] Clark MA, Hammond FR, Papaioannou A, et al. Regulation and expression of human Fab under the control of the Escherichia coli arabinose promoter, pBAD [J]. Immunotechnology, 1997, 3 (3): 217-26.